Investing in Biotech is a Long Game: Schulman

The video discusses the risks and rewards of investing in biotech, emphasizing the importance of patient capital and diversified portfolios. It highlights the impact of COVID-19 on biotech investments, particularly in vaccine development and telemedicine. The need for understanding both science and the commercial market is stressed for successful biotech investments. Future opportunities in mental health, aging-related diseases, and AI in drug discovery are identified as promising areas.

What does the speaker mean by 'patient capital' in the context of biotech investments?

What are the risks associated with investing in biotech according to the text?

How has the coronavirus pandemic impacted the perception of science and investment in biotech?

How does the speaker view the relationship between telemedicine and the changes brought about by the pandemic?

What factors should an investor consider beyond understanding the science in biotech investments?

What areas in biotech does the speaker express particular interest in for future investments?

What challenges does the aging population present in the context of biotech investments?